MedTrace Logo

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

NCT07165847 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-09-10

No results posted yet for this study

Summary

Neoadjuvant radiotherapy plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

Conditions

  • Immunotherapy
  • Gastric Cancer (GC)
  • Radiotherapy
  • Neoadjuvant Therapy
  • Neoadjuvant Chemoimmunotherapy

Interventions

DRUG

Iparomlimab and Tuvonralimab

q3w Iparomlimab and Tuvonralimab 5mg/kg on day 1 of each cycle

DRUG

Oxaliplatin

130mg/m2 on day 1 of each cycle

DRUG

Tegafur

\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid

RADIATION

Radiotherapy

30 Gy/10 fractions

Sponsors & Collaborators

  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

    lead OTHER

Principal Investigators

  • Bin Wang · Army Medical Center of the People's Liberation Army

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-23
Primary Completion
2028-09-23
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07165847 on ClinicalTrials.gov